Summary Thalidomide enhances de novo IgM antibody synthesis in mice to DNP Ficoll. The immunocompetent cells responsive to thymic independent antigens like DNP-Ficoll are macrophages and the B lymphocytes. Enhancement ofimmunores ponsiveness to DNP-Ficoll seems to be due to augmentation of macrophage fu nction by thalidomide.Since 1965, thalidomide has been used in alleviating the signs and symptoms of a major medical complication of lepromatous leprosy, erythema nodosum lepro sum (ENL).I Histologically, the hallmarks of ENL lesions are vasculitis or vascular necrosis, oedema and inflammation with infiltrates of neutrophils affecting the entire dermis and subcutaneous fa t.2 The factor or fa ctors that trigger the influx of neutrophils is unknown. For thalidomide to be effective in ENL, it must interfere with one or more of the essential steps in the pathogenesis of this syndrome.Since it has been suggested that ENL is an immune complex mediated disease,3, 4 we have investigated the effect of thalidomide on humoral immunolo gical responses. Thalidomide significantly inhibits an IgM but · not an IgG response in mice to the T-cell-dependent antigen, sheep erythrocytes; it also selectively decreases serum IgM concentrations among leprosy patients being treated fo r their ENL. 5 These observations have prompted us to speculate that a clinically relevant site of action fo r thalidomide in ENL is on the synthesis ofIgM antibody. If thalidomide acts on immunocompetent cells, the cell target of the drug must be among the macrophage, IgM antibody fo rming B cell and helper or suppressor lymphocytes.0305-75 18/85/056297 + 05 SO 1 .00
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.